BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma, Inc. insider activity centers on trusts associated with its Chief Executive Officer. A Form 4 reports that on January 8 and 9, 2026, the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, for which the CEO is a co‑trustee, sold multiple blocks of BridgeBio common stock under a Rule 10b5‑1 sales plan adopted on March 31, 2025.
The reported weighted average sale prices for these transactions range from about $73.05 to $78.32 per share, with examples including 11,515 shares at a weighted average price of $73.6446 and 10,519 shares at $77.6086. Following the reported trades, the family irrevocable trust held 715,686 shares, the revocable trust held 4,518,447 shares, and 228,776 shares were held directly. The reporting person disclaims beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest.
BridgeBio Pharma furnished an update with preliminary, unaudited financial figures for the quarter and fiscal year ended December 31, 2025. The company estimates it had approximately $587.5 million of cash, cash equivalents and marketable securities as of December 31, 2025. It also estimates net product revenue of $146.0 million for the fourth quarter of 2025 and $362.4 million for the full year 2025.
The company emphasized that these numbers are preliminary and subject to change as the year-end audit is completed. BridgeBio also presented a business update at the 44th Annual J.P. Morgan Healthcare Conference, and made its presentation slides available as an exhibit and on its website.
A holder of BridgeBio Pharma (BBIO) common stock filed a notice of intent to sell 120,000 shares under Rule 144. The shares are common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,912,400 and 192,708,813 common shares outstanding. The seller originally acquired these 120,000 shares on 03/26/2016 via conversion of management incentive units from the issuer.
The filing also lists recent sales made under Rule 10b5-1 trading plans over the prior three months by Neil Kumar and related trusts. Examples include 30,011 common shares sold on 12/15/2025 for gross proceeds of $2,239,901.00, and 20,000-share transactions on multiple dates in November and October 2025 by revocable and irrevocable trusts associated with the same address. The signer represents they are not aware of undisclosed material adverse information about the issuer.
The Form 144 notice for BBIO discloses a planned sale of 100000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 7427000.00. These shares are part of a class with 192708813 shares outstanding and are expected to be sold on or about 01/08/2026 on the NASDAQ.
The securities to be sold were acquired on 03/26/2016 via conversion of management incentive units from the issuer, with no gift indicated. The notice also lists multiple Rule 10b5-1 sales of common stock during the prior three months for accounts associated with NEIL KUMAR and related trusts, each disclosing the date, number of shares sold, and gross proceeds.
BridgeBio Pharma's chief executive officer and director reported multiple stock transactions in December 2025. On December 12, 2025, 60,975 restricted stock units converted into common stock, and 30,964 shares were withheld to satisfy tax obligations linked to this vesting.
On December 15, 2025, the officer sold 28,311 shares at a weighted average price of $74.5997 and 1,700 shares at $75.2412 under a Rule 10b5-1 sales plan adopted on March 31, 2025. After these transactions, the officer directly owned 228,776 shares, with an additional 755,686 and 4,558,447 shares held indirectly through family trusts, subject to a disclaimer of beneficial ownership beyond any pecuniary interest.
BridgeBio Pharma, Inc. reported an insider equity transaction by its President and CFO. On 12/12/2025, 13,826 shares of the company’s common stock were withheld at $75.15 per share to cover the executive’s tax obligations related to equity compensation.
The tax withholding was connected to the vesting of 25,000 shares of common stock underlying the executive’s restricted stock units. Following this transaction, the reporting officer directly beneficially owns 369,004 shares of BridgeBio Pharma common stock.
BridgeBio Pharma, Inc. reported an equity transaction by its Chief Accounting Officer, Maricel Apuli. On 12/12/2025, 2,003 shares of common stock were withheld to satisfy the officer's tax obligation arising from the vesting of 3,944 restricted stock units. The transaction price reported for the withheld shares was $75.15 per share. After this withholding, the officer beneficially owned 128,294 shares of BridgeBio Pharma common stock in direct ownership.
BridgeBio Pharma, Inc. (BBIO) Chief Executive Officer and director Kumar Haldea reported open-market sales of the company’s common stock on 11/20/2025 under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. He sold 6,401 shares at a weighted average price of $64.9706, 14,299 shares at a weighted average price of $65.904, and 5,456 shares at a weighted average price of $66.7129, with each price reflecting sales across specified ranges. Following these transactions, Haldea directly held 228,776 shares and also had indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust, where he serves as co-trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) director insider transactions were reported on a Form 4. A reporting person serving as a director disclosed open-market sales of BridgeBio common stock on 11/17/2025 and 11/18/2025 at weighted average prices ranging from about $64.58 to $67.20 per share, with specific weighted averages of $66.6263, $67.056, $65.2315, and $66.049 for the reported trades.
Following these transactions, the director beneficially owned 14,089 shares of common stock directly and 50,583 shares indirectly through joint tenancy with Nancy N. Lo. The price ranges for each trade are available, and the reporting person has undertaken to provide detailed breakdowns of the individual sale prices within each range upon request.
BridgeBio Pharma, Inc. (BBIO) director reports option exercise and share sales. On 11/17/2025, the reporting person exercised a stock option for 10,000 shares of common stock at $16.75 per share, increasing their holdings before subsequent sales. That same day, they sold 3,801 shares of common stock at a weighted average price of $66.2481 and 6,199 shares at a weighted average price of $66.8908, all under a Rule 10b5-1 trading plan adopted on June 27, 2025. After these transactions, the reporting person directly owned 11,589 shares of BridgeBio common stock and indirectly owned 4,000 shares through Thinking Bench Capital LLC. Following the option exercise, 41,501 stock options with a $16.75 exercise price remained beneficially owned.